Halozyme Therapeutics (NASDAQ:HALO) Releases Fiscal 2022 Earnings Guidance
Halozyme Therapeutics (NASDAQ:HALO – Get Rating) updated its earnings guidance for fiscal year 2022 on Tuesday. The company provided EPS guidance of $2,050 to $2,200 for the period, compared to the Thomson Reuters consensus EPS estimate of $2,180. The company released a revenue forecast of $530 million to $560 million, compared to a consensus revenue estimate of $554.20 million.
A number of research analysts have recently commented on the company. Piper Sandler reduced its price target on Halozyme Therapeutics from $43.00 to $42.00 in a Wednesday, February 23 report. Wells Fargo & Company cut its price target on Halozyme Therapeutics from $60.00 to $58.00 and set an overweight rating for the stock in a Wednesday, November 24 research note. raised its price target on Halozyme Therapeutics from $27.00 to $48.00 and gave the company a Buy rating in a Thursday, Dec. 2 research note. JMP Securities restated a buy rating and set a price target of $54.00 on shares of Halozyme Therapeutics in a Friday, Dec. 10 research note. Finally, Zacks Investment Research upgraded Halozyme Therapeutics from a strong sell rating to a hold rating and set a price target of $37.00 on the stock in a research note on Monday. Two investment analysts gave the stock a hold rating and five gave the stock a buy rating. According to MarketBeat, the stock currently has an average buy rating and consensus price target of $47.83.
Shares of Halozyme Therapeutics opened at $34.57 on Tuesday. The company has a current ratio of 7.91, a quick ratio of 7.45 and a debt ratio of 4.00. The company’s 50-day simple moving average is $34.83 and its 200-day simple moving average is $37.21. The stock has a market capitalization of $4.76 billion, a price-earnings ratio of 12.57 and a beta of 1.31. Halozyme Therapeutics has a 12-month low of $31.36 and a 12-month high of $51.57.
Several institutional investors have recently changed their positions in HALO. Silvercrest Asset Management Group LLC increased its position in Halozyme Therapeutics shares by 11.2% during the 4th quarter. Silvercrest Asset Management Group LLC now owns 8,758 shares of the biopharmaceutical company worth $352,000 after purchasing an additional 880 shares during the period. LPL Financial LLC increased its position in Halozyme Therapeutics by 42.0% in the fourth quarter. LPL Financial LLC now owns 24,589 shares of the biopharmaceutical company valued at $989,000 after acquiring an additional 7,271 shares during the period. Advisors Asset Management Inc. increased its position in Halozyme Therapeutics by 5.6% in the fourth quarter. Advisors Asset Management Inc. now owns 27,978 shares of the biopharmaceutical company valued at $1,125,000 after acquiring an additional 1,486 shares during the period. Deutsche Bank AG increased its position in Halozyme Therapeutics by 6.3% in the fourth quarter. Deutsche Bank AG now owns 111,307 shares of the biopharmaceutical company valued at $4,476,000 after acquiring an additional 6,617 shares during the period. Finally, California State Teachers Retirement System increased its position in Halozyme Therapeutics by 1.6% in the 4th quarter. California State Teachers Retirement System now owns 195,973 shares of the biopharmaceutical company valued at $7,880,000 after acquiring 3,170 additional shares during the period. Institutional investors and hedge funds own 90.21% of the company’s shares.
Halozyme Therapeutics Company Profile (Get a rating)
Halozyme Therapeutics, Inc operates as a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan and internationally. The Company’s products are based on ENHANZE drug delivery technology, a patented recombinant human hyaluronidase (rHuPH20) enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules. , as well as small molecules and fluids.
This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Halozyme Therapeutics right now?
Before you consider Halozyme Therapeutics, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Halozyme Therapeutics didn’t make the list.
Although Halozyme Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here